Pancreatic cancer remains a highly lethal malignancy frequently characterized by therapeutic resistance. The natural triterpenoid betulinic acid (BA) has demonstrated anticancer potential, but clinical application is limited by poor aqueous solubility and lack of organelle-specific delivery. Given widespread mitochondrial abnormalities in cancer cells, targeting mitochondria can enhance selective cytotoxicity and reduce systemic toxicity. The reported study used BA as a scaffold to develop mitochondria-directed derivatives aiming to improve potency against pancreatic cancer.
The authors designed and synthesized a library of 30 BA derivatives by conjugating delocalized lipophilic cations (DLCs) to the C-28 position of BA. Among the DLC motifs included was triphenylphosphonium (TPP+), an established mitochondrial targeting group that facilitates accumulation across the mitochondrial membrane potential. The synthesis strategy prioritized mitochondrial localization to exploit cancer cell bioenergetic and redox vulnerabilities.
A comprehensive in vitro activity screen against pancreatic cancer cells identified compound 14 as the lead molecule. Compound 14 exhibited potent cytotoxicity against PANC-1 cells with an IC50 of 1.36 ± 0.09 μM. By comparison, parent BA showed markedly lower activity (IC50 = 79.29 ± 6.87 μM), representing an approximately 58-fold improvement in potency for compound 14 over BA in this assay.
Transcriptomic profiling of treated cells was performed to explore molecular responses to compound 14. The data, together with mechanistic assays, supported mitochondrial accumulation of the derivative. The compound’s localization to mitochondria correlated with perturbations in pathways consistent with mitochondrial stress, excessive reactive oxygen species (ROS) generation, and downstream cell death programs.
Mechanistic studies showed that compound 14 induced excessive ROS production within cells, leading to collapse of the mitochondrial membrane potential (ΔΨm) and mitochondrial dysfunction. Mitochondrial impairment led to cytochrome c release into the cytosol and subsequent activation of the caspase cascade, consistent with initiation of intrinsic, mitochondria-mediated apoptosis. These observations indicate the compound triggers classic mitochondria-dependent apoptotic signaling following oxidative stress and loss of ΔΨm.
In addition to apoptosis, compound 14 promoted hallmarks of ferroptosis, a regulated cell death modality linked to iron-dependent lipid peroxidation. Specifically, treatment with compound 14 upregulated ACSL4 and downregulated GPX4. These molecular changes were accompanied by increased lipid peroxidation products and elevated intracellular Fe2+, consistent with promotion of ferroptotic processes. The simultaneous activation of apoptosis and ferroptosis suggests a multimodal cytotoxic mechanism that may overcome certain resistance mechanisms.
The role of ROS in mediating the ferroptotic and apoptotic effects of compound 14 was evaluated using the ROS scavenger N-acetylcysteine (NAC). NAC significantly reversed the ferroptosis-associated biochemical changes induced by compound 14, supporting that ROS generation is central to both the apoptotic and ferroptotic responses observed.
Compound 14 was evaluated in xenograft tumor models to assess antitumor efficacy and tolerability. In vivo, compound 14 significantly inhibited tumor growth compared with controls. The authors reported no evident systemic toxicity in treated animals, suggesting a favorable safety profile in the preclinical setting. Detailed dosing regimens, pharmacokinetics, and full safety measurements were not reproduced here beyond the summary provided in the source.
The study reports that a mitochondria-targeted BA derivative, compound 14, exerts potent antipancreatic cancer activity through ROS-driven mitochondrial apoptosis and induction of ferroptosis. Compound 14 showed substantially improved in vitro potency relative to BA, accumulated in mitochondria, disrupted ΔΨm, activated caspase-dependent apoptosis, and modulated ferroptosis regulators (upregulating ACSL4 and downregulating GPX4) with associated lipid peroxidation and increased Fe2+. ROS scavenging with NAC attenuated these effects. In vivo, compound 14 inhibited tumor growth in xenografts without evident systemic toxicity. The authors conclude compound 14 has favorable efficacy and safety in preclinical models and is a candidate for further preclinical development as a mitochondria-targeted therapeutic approach for pancreatic cancer.
Note: The source provided key experimental outcomes and mechanistic findings; full experimental details, dosing schedules, and broader safety and pharmacokinetic data were not included in the abstract and therefore are not detailed here.